Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Thank you

<< Previous

Bullboard Posts

Next >>

Comment by NamesJebon Dec 11, 2020 7:03pm

225 Views

Post# 32091479

RE:RE:RE:Thank you

My apologies, I wasn't clear. I was more referencing the fact that each of these markets (ipf, chronic cough, and covid-19) have estimated market values forcast over the next 2-5 years. By taking even the smallest of valuations, being IPF at 3.5 billion by 2023 we would arrive at a valuation of aprox 25X if we entirely took over the IPF market alone.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter